Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights GlobeNewswire - Tue May 12, 3:01PM CDT

Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings...

NKTX : 2.51 (-9.39%)
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers GlobeNewswire - Wed Apr 15, 3:01PM CDT

Expanded treatment in community settings will reduce patient burden Option to redose patients granted in both Ntrust-1 and Ntrust-2 studies Rheumatoid arthritis cohort to be added to Ntrust-2 ...

NKTX : 2.51 (-9.39%)
Nkarta to Participate in Needham Virtual Healthcare Conference GlobeNewswire - Thu Apr 9, 6:00AM CDT

SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 2.51 (-9.39%)
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights GlobeNewswire - Wed Mar 25, 3:01PM CDT

Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation...

NKTX : 2.51 (-9.39%)
Nkarta to Participate in March Investor Conferences GlobeNewswire - Fri Feb 27, 7:00AM CST

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 2.51 (-9.39%)
Nkarta to Participate in Evercore Healthcare Conference GlobeNewswire - Tue Dec 2, 2025

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 2.51 (-9.39%)
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights  GlobeNewswire - Mon Nov 10, 2025

Enrollment now underway in second dose-escalation cohort  Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide...

NKTX : 2.51 (-9.39%)
Nkarta to Participate in November Investor Conferences GlobeNewswire - Thu Oct 30, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 2.51 (-9.39%)
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting GlobeNewswire - Wed Oct 22, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

NKTX : 2.51 (-9.39%)
Nkarta to Participate in a September Investor Conference GlobeNewswire - Tue Sep 2, 2025

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...

NKTX : 2.51 (-9.39%)

Barchart Exclusives

Tesla Sales in China Are Popping, But That Means Nothing If You Can’t Stomach TSLA Stock’s Absurd P/E Ratio Barchart - Sat Jun 6, 3:00PM CDT
Tesla China sales jumped almost 40% in May as its FSD software rolled out globally. Here's why TSLA stock still belongs on your watch list now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.